AlphAIAlphAI — Financial news for AI agents
finanznachrichten.de$OSTX

OS Therapies: OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies (OSTX) has initiated a Conditional Marketing Authorisation Application (CMAA) with the U.K. MHRA for Herlystic (OST-HER2) to prevent or delay recurrence in pulmonary metastatic osteosarcoma. The company expects to complete the submission in Q4 2026, with a potential early market access decision from MHRA in Q1 2027. Herlystic has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

Original reporting
finanznachrichten.de
Published Nov 10, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 1:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$OSTX
Bullish
high confidence
Mentioned
$OSTX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$OSTXBullishMed
01

Why it matters

The regulatory filing represents the first public disclosure of the CMAA process, a material catalyst for the company's valuation.

02

Market read

The news could drive short‑term buying interest in OSTX and influence sentiment across the biotech sector.

03

What to watch

The company's reliance on future PRV sales and the need for a U.S. BLA add execution risk not captured in the headline.

Relevance 8/10Novelty 8/10Timing: Q4 2026 submission, decision expected Q1 2027

Background

OS Therapies is a clinical‑stage oncology company developing Listeria‑based immunotherapies, with OST‑HER2 holding multiple orphan and fast‑track designations.

Company-level read

Ticker impact

$OSTXBullishHigh confidence
Context

OS Therapies announced initiation of a Conditional Marketing Authorisation Application with the U.K. MHRA for Herlystic (OST-HER2), a new regulatory step not previously disclosed.

Expected impact

potential upside as investors price in the chance of regulatory approval

Evidence & confidence

Regulatory progress is a key catalyst for biotech valuations; the filing is a fresh development with limited downside risk.

Market effects

Sector

Positive signal for the oncology biotech sector as regulatory pathways for gene‑edited therapies gain momentum.

Regional

May boost U.K. biotech sentiment and could influence European regulators to align with MHRA decisions.

Global

Adds to global interest in orphan‑drug designations and priority review vouchers, potentially affecting related biotech stocks.

Counterpoint

What could challenge this read

If the CMAA is denied, the stock could face a sharp decline, making the current optimism risky.

Key entities

  • Company
    OS Therapies, Inc.

    Clinical‑stage oncology firm developing OST‑HER2.

  • Regulator
    MHRA

    U.K. Medicines and Healthcare products Regulatory Agency overseeing the CMAA.

Read at source← All news

StoryOS Therapies Opens UK Regulatory Filing for Herlystic

Also covered by

1 outlet

Related articles

$OSTXMed

OS Therapies (OSTX) Begins U.K. Marketing Application for Herlystic

OS Therapies (OSTX) has started the U.K. MHRA Conditional Marketing Authorisation Application for Herlystic, targeting pulmonary metastatic osteosarcoma. The company anticipates finishing this process in late Q4 2026, following a September 2026 scientific advice meeting. The next steps include completing the U.K. application and pursuing European filings.

tradingview.com
$OSTXMedAI 8/10

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

OS Therapies (OSTX) completed requalification of its Phase 2b drug substance for OST-HER2, enabling regulatory submissions in the U.S., U.K., and Europe. The company plans to file for approval in Q4 2026 and expects regulatory decisions in 2027. OST-HER2 has received multiple designations from the FDA and EMA, expediting the review process. The company has sufficient funding through mid-2027.

nugget.ca
$OSTXHighAI 8/10

A cancer drugmaker gets $7.2 million. It plans to seek approval for its treatment in four regions this quarter.

OS Therapies Inc. (OSTX) raised $7.2 million from a warrant exercise and exchange offer, with proceeds to fund regulatory filings for Herlystic™, its cancer immunotherapy, in the U.S., U.K., Europe, and Australia. The company plans to submit approval applications in Q4 2026 and expects the funds to support operations through key milestones.

stocktitan.net
$OSTXMedAI 8/10

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies (NYSE American: OSTX) reported a 72.7% 3-year overall survival rate for OST-HER2-treated patients in its Phase 2b trial, compared to 45.8% in historical controls. The company plans to submit regulatory applications for early market access in the U.S., U.K., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

finance.yahoo.com